Algert Global LLC bought a new stake in shares of Pharmerica Corporation (NYSE:PMC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 51,413 shares of the company’s stock, valued at approximately $1,350,000. Algert Global LLC owned about 0.17% of Pharmerica Corporation as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of Pharmerica Corporation by 124.5% in the second quarter. Russell Investments Group Ltd. now owns 4,886 shares of the company’s stock valued at $128,000 after buying an additional 2,710 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Pharmerica Corporation during the first quarter valued at $121,000. State of Alaska Department of Revenue increased its stake in shares of Pharmerica Corporation by 79.8% in the second quarter. State of Alaska Department of Revenue now owns 6,112 shares of the company’s stock valued at $160,000 after buying an additional 2,712 shares in the last quarter. US Bancorp DE increased its stake in shares of Pharmerica Corporation by 41.3% in the first quarter. US Bancorp DE now owns 7,121 shares of the company’s stock valued at $167,000 after buying an additional 2,081 shares in the last quarter. Finally, Mason Street Advisors LLC increased its stake in shares of Pharmerica Corporation by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,200 shares of the company’s stock valued at $168,000 after buying an additional 474 shares in the last quarter. Institutional investors own 94.25% of the company’s stock.
Pharmerica Corporation (PMC) remained flat at $29.05 during trading on Friday. The stock had a trading volume of 497,567 shares. The firm has a market capitalization of $904.07 million, a PE ratio of 39.36 and a beta of 0.92. Pharmerica Corporation has a 52-week low of $19.20 and a 52-week high of $29.10. The company has a 50-day moving average price of $27.05 and a 200-day moving average price of $25.07.
Pharmerica Corporation (NYSE:PMC) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.47. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The company had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. During the same quarter in the previous year, the firm posted $0.47 EPS. The business’s revenue was up 13.9% compared to the same quarter last year. Equities research analysts forecast that Pharmerica Corporation will post $1.92 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/19/51413-shares-in-pharmerica-corporation-pmc-acquired-by-algert-global-llc-updated.html.
Several brokerages have recently weighed in on PMC. Barrington Research downgraded Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. KeyCorp downgraded Pharmerica Corporation to an “overweight” rating in a research note on Wednesday, August 2nd. BidaskClub downgraded Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. UBS AG restated a “neutral” rating and set a $29.25 target price (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Finally, Credit Suisse Group downgraded Pharmerica Corporation from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $28.83.
About Pharmerica Corporation
What are top analysts saying about Pharmerica Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharmerica Corporation and related companies.